Supplementary Fig. 3 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

<p>Supplementary Fig 3 In vivo cellular and humoral responses through 52 weeks are illustrated here.</p>